Rasheed Razia Abdul, Venkatraman G, Vijayalakshmi S, Raja T A R, Senthil G, Renugadevi P
Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India.
Department of Orthopaedics, Vels Medical College and Hospital, Tiruvallur, Tamil Nadu, India.
Indian J Pharmacol. 2024 Sep 1;56(5):317-321. doi: 10.4103/ijp.ijp_107_24. Epub 2024 Dec 16.
Long-term metabolic disease type 2 diabetes mellitus (T2DM) is distinguished by elevated blood glucose, insulin resistance, and drought of insulin with dyslipidemia. Oral hypoglycemic agents lower blood glucose levels as well as prevent both short-term and long-term complications such as micro/macrovascular atherosclerosis, chronic kidney diseases, and chronic heart disease. This study aims to compare the effect of glimepiride versus teneligliptin in combination with metformin in T2DM patients attending a tertiary care hospital.
This prospective, randomized, open-label study was initiated in a tertiary care hospital after obtaining IEC approval. Written informed consent was obtained. The sample size was calculated using "Statistics and sample size software." Ninety-seven patients satisfying the inclusion criteria were assigned to two groups using simple randomization with allocation 1:1. Group A received metformin + glimepiride while Group B received metformin + teneligliptin for 12 weeks. Fasting blood sugar (FBS), postprandial blood sugar (PPBS), glycated hemoglobin (HbA1c), and lipid profile were recorded at the baseline and at the end of 12 weeks. This study was conducted for 1 year. Data were analyzed using SPSS version 23.0 software.
Out of 97 participants (Group A: 48 and Group B: 49), Group A showed a higher reduction in FBS (48.18 ± 9.64) whereas Group B showed 72.53 ± 5.01, 1.74 ± 0.42 of change in PPBS and HbA1c after 12 weeks.
The study found that combining metformin with teneligliptin was better tolerated and improved glycemic control and lipid profile compared to metformin plus glimepiride.
长期代谢性疾病2型糖尿病（T2DM）的特征是血糖升高、胰岛素抵抗以及伴有血脂异常的胰岛素缺乏。口服降糖药可降低血糖水平，并预防短期和长期并发症，如微血管/大血管动脉粥样硬化、慢性肾脏疾病和慢性心脏病。本研究旨在比较格列美脲与替格列汀联合二甲双胍对三级医院就诊的T2DM患者的疗效。
本前瞻性、随机、开放标签研究在获得伦理委员会批准后于一家三级医院开展。获取了书面知情同意书。使用“统计与样本量软件”计算样本量。97名符合纳入标准的患者通过简单随机化以1:1的比例分为两组。A组接受二甲双胍+格列美脲，而B组接受二甲双胍+替格列汀，疗程为12周。在基线和12周结束时记录空腹血糖（FBS）、餐后血糖（PPBS）、糖化血红蛋白（HbA1c）和血脂谱。本研究进行了1年。使用SPSS 23.0软件进行数据分析。
在97名参与者中（A组：48名，B组：49名），A组FBS降低幅度更大（48.18±9.64），而B组在12周后PPBS和HbA1c的变化分别为72.53±5.01、1.74±0.42。
研究发现，与二甲双胍加格列美脲相比，二甲双胍与替格列汀联合使用耐受性更好，血糖控制和血脂谱得到改善。
